Skip to main content

Table 4 Proportion of AEs according to patients’ sex and genotype

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

 

TH

BZB

 

TH treatment

TH AE

% of pts with AE

BZB treatment

BZB AE

% of pts with AE

male pts

41

25

61

23

6

26

female pts

26

12

46a

46

27

59b

ENG pts

17

17

100

10

2

20c

ACVRL1 pts

34

14

41

57

17

30d

  1. Comparing males to females : ap=0.32, b<0.01. Comparing thalidomide to bevacizumab, cp<0.001, d=0.36